This case-based online mentor workshop podcast focuses on practical strategies to manage metastatic breast cancer in your patients with triple negative disease. Presented by Lyndsay N. Harris, MD, it includes prerecorded Q & A from the proceedings of live audioconferences. This workshop podcast is a…
Dr. Harris answers additional questions from the live audience on topics such as the role of erlotinib in triple-negative BC and the MOA of PARP inhibitors, and concludes the podcast with take-away messages regarding triple-negative BC.
Dr. Harris answers questions from the live audience on topics such as the role of biopsy, selecting 2nd- and 3rd-line regimens, the role of vitamin D, and the use of platinums in triple-negative BC.
Dr. Harris reviews the role of NCCN guidelines and clinical trial data in making treatment decisions for patients with BC.
Dr. Harris discusses the patient’s participation in a phase II trial of iniparib and the MOA of PARP inhibitors.
Dr. Harris describes recommendations for staging patients with early disease and recommendations individualizing these according to patient and disease characteristics.
Dr. Harris discusses the diagnosis, staging, and initial treatment of triple-negative breast cancer in a 39-year-old woman with a family history of breast cancer (BC).